Clopidogrel hydrogensulfate
99%
- Product Code: 100130
Alias:
Clopidogrel hydrogen sulfate; Clopidogrel hydrogen sulfate; 2-(2-Chlorophenyl)-2-(6,7-dihydrothieno[3,2-C]pyridin-5-yl)methyl acetate sulfate hydrogen salt
CAS:
135046-48-9
Properties:
This product is for scientific research only
Molecular Weight: | 419.90 g./mol | Molecular Formula: | C₁₆H₁₆ClNO₂SH₂SO₄ |
---|---|---|---|
EC Number: | MDL Number: | MFCD05865229 | |
Melting Point: | Boiling Point: | ||
Density: | Storage Condition: | 2-8°C |
Product Description:
Used primarily as an antiplatelet medication to prevent blood clots in patients with conditions such as heart disease, stroke, and peripheral artery disease. It is often prescribed after heart attacks, stents, or bypass surgery to reduce the risk of further cardiovascular events. Works by inhibiting platelet aggregation, making it effective in preventing thrombotic disorders. Commonly administered in combination with aspirin for enhanced efficacy in certain cases. Also used in the management of acute coronary syndrome and to prevent clot formation in patients with atrial fibrillation who cannot take anticoagulants.
Product Specification:
Test | Specification |
---|---|
Appearance | White To Off-White Solid |
Purity (%) | 98.5-100 |
HNMR | Consistent With Structure |
Sizes / Availability / Pricing:
Size (g) | Availability | Price | Quantity |
---|---|---|---|
0.100 | 10-20 days | $24.50 |
+
-
|
0.500 | 10-20 days | $36.55 |
+
-
|
1.000 | 10-20 days | $50.25 |
+
-
|
5.000 | 10-20 days | $139.54 |
+
-
|
Clopidogrel hydrogensulfate
Used primarily as an antiplatelet medication to prevent blood clots in patients with conditions such as heart disease, stroke, and peripheral artery disease. It is often prescribed after heart attacks, stents, or bypass surgery to reduce the risk of further cardiovascular events. Works by inhibiting platelet aggregation, making it effective in preventing thrombotic disorders. Commonly administered in combination with aspirin for enhanced efficacy in certain cases. Also used in the management of acute coronary syndrome and to prevent clot formation in patients with atrial fibrillation who cannot take anticoagulants.
Mechanism | - |
Appearance | - |
Longevity | - |
Strength | - |
Storage | - |
Shelf Life | - |
Allergen(s) | - |
Dosage (Range) | - |
Recommended Dosage | - |
Dosage (Per Day) | - |
Recommended Dosage (Per Day) | - |
Mix Method | - |
Heat Resistance | - |
Stable in pH range | - |
Solubility | - |
Product Types | - |
INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :